Table 2.

Surgery and chemotherapy outcomes in 31 patients with predominant plasmacytoid histology

	No. Pts (%)
Surgery type:
No surgery	9 (29)
Cystectomy/cystoprostatectomy	17 (55)
Exenteration	2 (6)
Transurethral bladder tumor resection	2 (6)
Surgery aborted due to T4b stage	3 (10)
Unknown	1 (3)
Lymph node dissection:
Yes	20 (65)
No	9 (29)
Unknown	2 (6)
Lymph node status at surgery:
Pos	11 (35)
Neg	9 (29)
Not applicable (no surgery or no lymph node dissection)	10 (32)
Unknown	1 (3)
Margin status at surgery:
Pos	2 (6)
Neg	18 (58)
Not applicable (no surgery or unreported margins)	10 (32)
Unknown	1 (3)
Pathological CR:
Yes	4 (13)
No	17 (55)
Not applicable (no or aborted surgery)	9 (29)
Unknown	1 (3)
Chemotherapy setting:
None	3 (10)
Neoadjuvant	7 (23)
Adjuvant	7 (23)
Metastatic	14 (45)
Best chemotherapy response:
CR (tumor resolution on imaging)	6 (19)
Less than CR on imaging	10 (32)
Stable disease	1 (3)
Progressive disease	1 (3)
Unknown	2 (6)
Not applicable (adjuvant or no chemotherapy)	11 (35)
Chemotherapy type:*
Dose dense MVAC	14 (45)
Ifosfamide, doxorubicin + gemcitabine	8 (26)
GC based	6 (19)
Other	6 (19)
Unknown	1 (3)
None	3 (10)
Post-chemotherapy progression site:†
Peritoneum	19 (61)
Retroperitoneal lymph nodes	3 (10)
Bladder	3 (10)
Bone, lungs, scrotum	3 (10)
Unknown	3 (10)
No progression	5 (16)

^*CR plus partial response in 7 of 9 patients with dose dense MVAC, 6 of 7 (86%) with ifosfamide, doxorubicin and gemcitabine, all 5 (100%) with GC based chemotherapy and 3 of 4 (75%) with other chemotherapy, not including those with adjuvant chemotherapy or missing response data and with percents totaling greater than 100% since some patients received more than 1 regimen.

^†Some patients had progression at different sites.